398 related articles for article (PubMed ID: 17045935)
1. Decision support tool to individualize cyclosporine dose in stable, long-term heart transplant recipients receiving metabolic inhibitors: overcoming limitations of cyclosporine C2 monitoring.
Ray JE; Keogh AM; McLachlan AJ
J Heart Lung Transplant; 2006 Oct; 25(10):1223-9. PubMed ID: 17045935
[TBL] [Abstract][Full Text] [Related]
2. Cyclosporin C(2) and C(0) concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors.
Ray JE; Keogh AM; McLachlan AJ; Akhlaghi F
J Heart Lung Transplant; 2003 Jul; 22(7):715-22. PubMed ID: 12873538
[TBL] [Abstract][Full Text] [Related]
3. A limited sampling strategy for the estimation of 12-hour cyclosporine neoral area under the curve in Chinese cardiac transplant recipients.
Wang CH; Ko WJ; Chou NK; Wang SS
Transplant Proc; 2004 Oct; 36(8):2390-2. PubMed ID: 15561259
[TBL] [Abstract][Full Text] [Related]
4. Correlation Between C2 and AUC(0-4) in Renal Transplant Patients Treated With Diltiazem.
Aros CA; Schneider HO; Flores CA; Ardiles LG; Alruiz PA; Jerez V; Mezzano SA
Transplant Proc; 2005 Apr; 37(3):1580-2. PubMed ID: 15866679
[TBL] [Abstract][Full Text] [Related]
5. Effect of diltiazem on the pharmacokinetics of microemulsion cyclosporine A in renal transplantation.
Bunnag S; Vareesangthip K; Ong-ajyooth L
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S228-34. PubMed ID: 17044476
[TBL] [Abstract][Full Text] [Related]
6. Monitoring C2 level predicts exposure in maintenance lung transplant patients receiving the microemulsion formulation of cyclosporine (Neoral).
Jaksch P; Kocher A; Neuhauser P; Sarahrudi K; Seweryn J; Wisser W; Klepetko W
J Heart Lung Transplant; 2005 Aug; 24(8):1076-80. PubMed ID: 16102443
[TBL] [Abstract][Full Text] [Related]
7. Study of cyclosporine level at 2 hours after administration in preoperative kidney transplant recipients for prediction of postoperative optimal cyclosporine dose.
Sukhavasharin N; Praditpornsilpa K; Avihingsanon Y; Kuoatawintu P; O-Charoen R; Kansanabuch T; Tungsanga K; Eiam-Ong S
J Med Assoc Thai; 2006 Aug; 89 Suppl 2():S15-20. PubMed ID: 17044449
[TBL] [Abstract][Full Text] [Related]
8. Achieving adequate cyclosporine exposure in liver transplant recipients: a novel strategy for monitoring and dosing using intravenous therapy.
Lück R; Böger J; Kuse E; Klempnauer J; Nashan B
Liver Transpl; 2004 May; 10(5):686-91. PubMed ID: 15108262
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring of cyclosporine Neoral in de novo Chinese cardiac transplant recipients treated with an everolimus-cyclosporine immunosuppressive regimen.
Wang CH; Chou NK; Wu FL; Ko WJ; Tsao CI; Chi NH; Hsu RB; Wang SS
Transplant Proc; 2006 Sep; 38(7):2132-4. PubMed ID: 16980022
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery.
Banner NR; David OJ; Leaver N; Davis J; Breen J; Johnston A; Yacoub MH
Transpl Int; 2002 Dec; 15(12):649-54. PubMed ID: 12478413
[TBL] [Abstract][Full Text] [Related]
11. Single time point measurement by C2 or C3 is highly predictive in cyclosporine area under the curve estimation immediately after lung transplantation.
Hangler HB; Ruttmann E; Geltner C; Bucher B; Nagiller J; Laufer G; Mueller LC
Clin Transplant; 2008; 22(1):35-40. PubMed ID: 18217903
[TBL] [Abstract][Full Text] [Related]
12. Limitations of cyclosporine C2 monitoring in pediatric heart transplant recipients.
Hmiel SP; Canter C; Shepherd R; Lassa-Claxton S; Nadler M
Pediatr Transplant; 2007 Aug; 11(5):524-9. PubMed ID: 17631021
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics and bayesian estimator of cyclosporine in pediatric renal transplant patients.
Irtan S; Saint-Marcoux F; Rousseau A; Zhang D; Leroy V; Marquet P; Jacqz-Aigrain E
Ther Drug Monit; 2007 Feb; 29(1):96-102. PubMed ID: 17304156
[TBL] [Abstract][Full Text] [Related]
14. Hepatotoxicity associated with cyclosporine monitoring using C2 recommendations in adults renal recipients receiving ketoconazole.
Videla C; Vega J; Borja H
Transplant Proc; 2005 Apr; 37(3):1574-6. PubMed ID: 15866677
[TBL] [Abstract][Full Text] [Related]
15. Two-hour postdose concentration: a reliable marker for cyclosporine exposure in adolescents with stable renal transplants.
John U; Ullrich S; Roskos M; Misselwitz J
Transplant Proc; 2005 Apr; 37(3):1608-11. PubMed ID: 15866686
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic drug monitoring of tacrolimus in cardiac transplant recipients: a comparison with cyclosporine neoral.
Wang CH; Ko WJ; Chou NK; Wang SS
Transplant Proc; 2004 Oct; 36(8):2386-7. PubMed ID: 15561257
[TBL] [Abstract][Full Text] [Related]
17. Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients.
Davies RA; Veinot JP; Williams K; Haddad H; Baker A; Donaldson J; Pugliese C; Struthers C; Masters RG; Hendry PJ; Mesana T
Transplant Proc; 2007 Dec; 39(10):3334-9. PubMed ID: 18089382
[TBL] [Abstract][Full Text] [Related]
18. Limitations of C2 monitoring in renal transplant recipients.
Einecke G; Schütz M; Mai I; Fritsche L; Giessing M; Glander P; Neumayer HH; Budde K
Nephrol Dial Transplant; 2005 Jul; 20(7):1463-70. PubMed ID: 15840681
[TBL] [Abstract][Full Text] [Related]
19. Association between cyclosporine concentrations at 2 hours post-dose and clinical outcomes in de novo lung transplant recipients.
Akhlaghi F; Gonzalez L; Trull AK
J Heart Lung Transplant; 2005 Dec; 24(12):2120-8. PubMed ID: 16364860
[TBL] [Abstract][Full Text] [Related]
20. Effect of gastrointestinal inflammation and age on the pharmacokinetics of oral microemulsion cyclosporin A in the first month after bone marrow transplantation.
Schultz KR; Nevill TJ; Balshaw RF; Toze CL; Corr T; Currie CJ; Strong DK; Keown PA
Bone Marrow Transplant; 2000 Sep; 26(5):545-51. PubMed ID: 11019845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]